Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects
An. bras. dermatol
; 93(4): 529-534, July-Aug. 2018. tab, graf
Article
em En
| LILACS
| ID: biblio-949909
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract Background:
Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a topical therapy for field cancerization in actinic keratosis.Objective:
To evaluate the clearance rate and adverse events in the treatment of actinic keratoses with ingenol mebutate.Methods:
A longitudinal, prospective, non-randomized, interventional, open, single-center study was conducted. Patients with actinic keratoses applied ingenol mebutate on a 25cm2 area of the face and/or scalp for three consecutive days (0.015%) or on the forearm for two days (0.05%).Results:
27 patients completed the protocol, of whom 13 on the face and/or scalp and 14 on the forearm. Complete clearance occurred in 53.8% in the first group and 42.8% in the second. Partial response was observed in 15.4% and 35.7%, respectively. The most common side effects were erythema, edema, desquamation, pruritus, and local erosion. Studylimitations:
The study had a small sample and was not randomized, double-blind, placebo-controlled, or vehicle-controlled.Conclusion:
Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period.Palavras-chave
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Diterpenos
/
Ceratose Actínica
Tipo de estudo:
Clinical_trials
/
Guideline
/
Observational_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article